These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11067651)

  • 1. Economic evaluations of influenza vaccination in healthy working-age adults. Employer and society perspective.
    Wood SC; Nguyen VH; Schmidt C
    Pharmacoeconomics; 2000 Aug; 18(2):173-83. PubMed ID: 11067651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seasonal influenza vaccination of healthy working-age adults: a review of economic evaluations.
    Gatwood J; Meltzer MI; Messonnier M; Ortega-Sanchez IR; Balkrishnan R; Prosser LA
    Drugs; 2012 Jan; 72(1):35-48. PubMed ID: 22191794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.
    Postma MJ; Jansema P; van Genugten ML; Heijnen ML; Jager JC; de Jong-van den Berg LT
    Drugs; 2002; 62(7):1013-24. PubMed ID: 11985488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.
    Nichol KL
    Arch Intern Med; 2001 Mar; 161(5):749-59. PubMed ID: 11231710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    Rothberg MB; Rose DN
    Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Issues in the economic evaluation of influenza vaccination by injection of healthy working adults in the US: a review and decision analysis of ten published studies.
    Hogan TJ
    Pharmacoeconomics; 2012 May; 30(5):355-71. PubMed ID: 22462695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine.
    Nichol KL; Mallon KP; Mendelman PM
    Vaccine; 2003 May; 21(17-18):2207-17. PubMed ID: 12706712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza vaccines in low and middle income countries: a systematic review of economic evaluations.
    Ott JJ; Klein Breteler J; Tam JS; Hutubessy RC; Jit M; de Boer MR
    Hum Vaccin Immunother; 2013 Jul; 9(7):1500-11. PubMed ID: 23732900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness.
    Prosser LA; O'Brien MA; Molinari NA; Hohman KH; Nichol KL; Messonnier ML; Lieu TA
    Pharmacoeconomics; 2008; 26(2):163-78. PubMed ID: 18198935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of influenza vaccination in working-age cancer patients.
    Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
    Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic impact of providing workplace influenza vaccination. A model and case study application at a Brazilian pharma-chemical company.
    Burckel E; Ashraf T; de Sousa Filho JP; Forleo Neto E; Guarino H; Yauti C; Barreto F de B; Champion L
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):563-76. PubMed ID: 10662481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Net Costs Due to Seasonal Influenza Vaccination--United States, 2005-2009.
    Carias C; Reed C; Kim IK; Foppa IM; Biggerstaff M; Meltzer MI; Finelli L; Swerdlow DL
    PLoS One; 2015; 10(7):e0132922. PubMed ID: 26230271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analyses.
    Nichol KL; Mendelman P
    Virus Res; 2004 Jul; 103(1-2):3-8. PubMed ID: 15163481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK.
    Das Gupta R; Guest JF
    Pharmacoeconomics; 2002; 20(7):475-84. PubMed ID: 12093303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of vaccination against influenza in New Zealand.
    Scott WG; Scott HM
    Pharmacoeconomics; 1996 Jan; 9(1):51-60. PubMed ID: 10160087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influenza vaccination in the elderly population in Mexico: economic considerations].
    Gutiérrez JP; Bertozzi SM
    Salud Publica Mex; 2005; 47(3):234-9. PubMed ID: 16104466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influenza vaccination of hospital healthcare staff from the perspective of the employer: a positive balance].
    Hak E; Knol LM; Wilschut JC; Postma MJ
    Ned Tijdschr Geneeskd; 2010; 154():A1188. PubMed ID: 20977784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old.
    Smith KJ; Nowalk MP; Lin CJ; Zimmerman RK
    Hum Vaccin Immunother; 2017 Oct; 13(10):2207-2212. PubMed ID: 28829719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic costs of influenza-related work absenteeism.
    Akazawa M; Sindelar JL; Paltiel AD
    Value Health; 2003; 6(2):107-15. PubMed ID: 12641861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of influenza vaccination of healthy children.
    Salo H; Kilpi T; Sintonen H; Linna M; Peltola V; Heikkinen T
    Vaccine; 2006 Jun; 24(23):4934-41. PubMed ID: 16678945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.